Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, which is more or less 9.11 % above the present share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the first quarter of 2021.
The present consensus among eleven TipRanks analysts is actually for a moderate Buy rating of shares in CVS Health, with an average price target of eighty four dolars.
The analysts priced targets range from a high of hundred one dolars to a low of $61.
From the latest earnings report of its, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.
Based on TipRanks.com, Merrill Lynch analyst Michael Cherny is presently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It runs through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Long or retail Term Care segment has selling of prescription drugs and assortment of general merchandise.
The Health Care Benefits segment offers quite traditional, consumer-directed and voluntary health insurance products and related services, which includes medical, pharmacy, dental, behavioural health, healthcare management abilities. The Corporate segment involves in offering administrative services and management. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.